Tensions stemming from the U.S.-China trade war escalated sharply over the last few days, with much happening as Asian markets were shut down for the weekend.China Economyread more
The latest round of tariff announcements in the last few days means that by the end of the year, essentially all Chinese goods exported to the U.S. will be subject to duties.China Economyread more
Futures fell after Trump said the U.S. will raise tariffs on more than $500 billion worth of Chinese imports, increasing trade tensions.Marketsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
China said Friday it will be resuming 25% duties on U.S. autos, and a further 5% on auto parts and components.Asia Marketsread more
World leaders, environmental groups and celebrities have publicly decried the vast swaths of forest being destroyed by the fires.World Newsread more
Education Minister Ong Ye Kung says the Singapore government has been preparing for the challenge of an aging workforce "for the past 20 years."Employmentread more
Stocks in Asia fell Monday morning following an escalation in the U.S.-China trade war late last week.Asia Marketsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Cramer always notes superlatives in any stock. What does he think of this play now?
Sometimes a 52-week high can be a sign of the top and other times it can suggest a break out lies ahead.
It's the latter scenario that Jim Cramer thinks is more likely as Seattle Genetics touched not only a 52-week high but an all time high on Monday.
"I still think it has more room to run," said the Mad Money host.
Cramer has been a fan of the space broadly and this company in particular for quite some time. In December 2012, the Mad Money host suggested putting Seattle Genetics on your radar as a potential buy. Had you pulled the trigger at that time, you'd already have an 85% gain.
But even if you missed those gains – the Mad Money host still sees opportunity.
He continues to believe powerful catalysts -- such as the ground breaking ways in which the company's products help patients battle cancer -- can drive shares even higher.
"The company uses antibody-based technology to search and destroy cancer cells, without causing collateral damage to healthy tissue that are nearby, " Cramer explained.
Cramer believes that is game changing. These drugs can offer an alternatives to conventional chemotherapy, which can sometimes be as damaging as the cancer it's intended to destroy.
And although the company's main product Adcetris, was approved for Hodgkin's Lymphoma two years ago, Cramer says it's possible it may be an effective treatment for other kinds of cancers too.
"Seattle Genetics has twenty other clinical trials going, studying this drug on various different forms of cancer, four of those trials are in phase 3, and that includes a fast-tracked study for T cell lymphoma," he said.
Read More from Mad Money with Jim Cramer
Cramer's top ideas for the week ahead
This $3 stock way too cheap?
Quiet developments demand attention, says Cramer
That's not only good news for patients in their fight against cancer, Cramer thinks it's also positive for investors who hold the stock.
"I'd look at it this way, Seattle Genetics has a lot of shots on goal," he said. And when you get many shots on goal, chances are, you score.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the "Mad Money" website? firstname.lastname@example.org